Verastem Oncology
117 Kendrick Street
Suite 500
Needham
MA
02494
United States
Tel: (718) 292-4200
Website: http://www.verastem.com/
Email: info@verastem.com
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
Founded: 2010
371 articles with Verastem Oncology
-
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
5/18/2022
Verastem Oncology today announced that it has received the first “Therapeutic Accelerator Award” from the Pancreatic Cancer Network (PanCAN).
-
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
5/9/2022
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 04, 2022
4/4/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 435,750 shares of its common stock and the grant of 240,900 restricted stock units to nine new employees.
-
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
3/28/2022
Verastem Oncology today reported financial results for the three months and full year ended December 31, 2021, and highlighted recent progress.
-
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
3/28/2022
Verastem Oncology today announced it has entered into a credit facility with Oxford Finance LLC for up to $150 million that is designed to primarily support the continued development, commercial preparation and potential launches of VS-6766 and defactinib.
-
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
3/24/2022
Verastem Oncology today announced that Channing Der, PhD, has been appointed to its Scientific Advisory Board.
-
Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers
1/11/2022
Verastem Oncology today outlined key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2022
1/7/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced the grant of options to purchase 1,625 shares of its common stock and the grant of 813 restricted stock units to two new employees.
-
Verastem Oncology to Participate in Upcoming Investor Conferences - Jan 04, 2022
1/4/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that the Company will participate virtually at the following upcoming investor conferences.
-
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
11/22/2021
Mirati Therapeutics, Inc. announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer.
-
Verastem Oncology to Present at the Jefferies London Healthcare Conference
11/11/2021
Verastem Oncology today announced that the Company will present at the Jefferies London Healthcare Conference.
-
Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
11/4/2021
Verastem Oncology today reported financial results for the three months ended September 30, 2021 and highlighted recent progress.
-
Verastem Oncology Appoints Michelle Robertson to Board of Directors
10/26/2021
Verastem Oncology today announced the appointment of Michelle Robertson to its Board of Directors, effective November 15, 2021.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 24, 2021
9/24/2021
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of options to purchase 450,000 shares of its common stock and the grant of 150,000 restricted stock units to Louis J. Denis, MD, in connection with his appointment to Chief Medical Officer.
-
Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
9/22/2021
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical development and oncology expertise to Verastem.
-
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
9/20/2021
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRAS TM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
-
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021
9/19/2021
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study.
-
Verastem Oncology to Present at Upcoming Investor Conferences in September 2021
9/7/2021
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that management will present virtually at the following upcoming investor conferences.
-
Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021
7/27/2021
Verastem Oncology announced that an abstract detailing updated results from the ongoing Phase 1/2 FRAME study investigating VS-6766, the Company’s RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low grade serous ovarian cancer has been selected for a mini oral presentation at the upcoming European Society of Medical Oncology Congress 2021, taking place virtually September 16-21, 2021.
-
Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt
7/19/2021
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that it has converted all of the $28.0 million aggregate principal of the Company’s 2020 5.00% Convertible Senior Notes due 2048 in exchange for approximately 8.6 million shares of the Company’s common stock, based on the Company’s existing Mandatory Conversion right.